Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Sacher

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
JACC. Cardiooncology|June 19, 2025
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent ToxicityMalak El-Rayes, Inbar Nardi Agmon, Christopher Yu, et al.
Therapeutic Advances in Medical Oncology|November 22, 2021
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancerBarbara Melosky, Parneet Cheema, Rosalyn A Juergens, et al.
Lung Cancer (Amsterdam, Netherlands)|August 6, 2021
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancerBarbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 28, 2020
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world dataAli Vedadi, Sharara Shakik, M Catherine Brown, et al.
JTO Clinical and Research Reports|January 2, 2026
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLCBeatriz Jimenez Munarriz, Sameena Khan, Katrina Hueniken, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistanceGrainne M O'Kane, Geoffrey Liu, Tracy L Stockley, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancerBarbara Melosky, Rosalyn A Juergens, Shantanu Banerji, et al.
The Canadian Journal of Urology|August 11, 2021
The financial impact of cancer care on renal cancer patientsDoreen A Ezeife, Brendon Josh Morganstein, Steven Yip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerDavid M Hwang, Tahani Albaqer, Rex C Santiago, et al.
Clinical Lung Cancer|February 25, 2019
Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care SystemDoreen A Ezeife, Brandon Josh Morganstein, Sally Lau, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
JACC. Cardiooncology|June 19, 2025
Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent ToxicityMalak El-Rayes, Inbar Nardi Agmon, Christopher Yu, et al.
Therapeutic Advances in Medical Oncology|November 22, 2021
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancerBarbara Melosky, Parneet Cheema, Rosalyn A Juergens, et al.
Lung Cancer (Amsterdam, Netherlands)|August 6, 2021
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancerBarbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 28, 2020
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world dataAli Vedadi, Sharara Shakik, M Catherine Brown, et al.
JTO Clinical and Research Reports|January 2, 2026
Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for <i>ALK-</i>Mutated NSCLCBeatriz Jimenez Munarriz, Sameena Khan, Katrina Hueniken, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistanceGrainne M O'Kane, Geoffrey Liu, Tracy L Stockley, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancerBarbara Melosky, Rosalyn A Juergens, Shantanu Banerji, et al.
The Canadian Journal of Urology|August 11, 2021
The financial impact of cancer care on renal cancer patientsDoreen A Ezeife, Brendon Josh Morganstein, Steven Yip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2021
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung CancerDavid M Hwang, Tahani Albaqer, Rex C Santiago, et al.
Clinical Lung Cancer|February 25, 2019
Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care SystemDoreen A Ezeife, Brandon Josh Morganstein, Sally Lau, et al.
Pageof 6